Zacks Investment Research upgraded shares of PHARMACYCLICS (PCYC) from NEUTRAL to OUTPERFORM on July 17, 2012, with a target price of $60.30.
Pharmacyclics Inc. is a pharmaceutical company developing products to improve upon therapeutic approaches to cancer, atherosclerosis and retinal disease. The company's products are ring-shaped small molecules called texaphyrins. These patented agents are derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. The texaphyrins localize in cancer cells, atherosclerotic plaque and neovasculature, where they can be activated by forms of energy, including X-rays and light to reduce diseased tissue.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PHARMACYCLICS (PCYC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment